中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

交易中 07-30 10:29:00

7.740

+0.190

+2.52%

最高7.750	最低7.340	成交量7,485万
今开7.450	昨收7.550	日振幅5.43%
总市值1,452亿	流通市值1,452亿	总股本187.61亿
成交额5.69亿	换手率0.40%	流通股本187.61亿
市净率4.15	ROE11.82%	每股收益0.21
52周最高7.750	52周最低2.651	市盈率36.99
股息0.07	股息收益率0.01	ROA5.62%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":7.74,"timestamp":1753842535556,"preClose":7.55,"halted":0,"volume":74819165,"delay":0,"floatShares":18761000000,"shares":18761000000,"eps":0.2092567883776061,"marketStatus":"交易中","change":0.19,"latestTime":"07-30 10:28:57","open":7.45,"high":7.75,"low":7.34,"amount":568562818,"amplitude":0.054305,"askPrice":7.74,"askSize":113000,"bidPrice":7.73,"bidSize":142000,"shortable":3,"etf":0,"ttmEps":0.2091922552750565,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1753848000000},"marketStatusCode":2,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":7.55,"dividendRate":0.009044,"openAndCloseTimeList":[[1753839000000,1753848000000],[1753851600000,1753862400000]],"volumeRatio":1.946206,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.6245,"impliedVolPercentile":0.9878},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2555544970","title":"默沙东、GSK豪赌，恒瑞上桌，AZ、罗氏血战，千亿赛道开卷！","url":"https://stock-news.laohu8.com/highlight/detail?id=2555544970","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555544970?lang=zh_cn&edition=full","pubTime":"2025-07-29 21:27","pubTimestamp":1753795620,"startTime":"0","endTime":"0","summary":"7月28日，恒瑞与GSK达成重磅合作，将共同开发至多12款创新药物。COPD仅次于心血管疾病和肿瘤，是全球第三大致死原因，却因为疾病复杂、药物选择有限而长期缺乏突破。7月9日，默沙东豪掷100亿美元收购Verona Pharma。默沙东在呼吸领域并非主角，但拿下恩塞芬汀后，局面出现改变。无疑，恒瑞凭借最新交易成为了当下COPD赛道的焦点。加之GSK 此次合作还包括另外11个早期项目，也被看作是恒瑞与全球TOP级MNC的深度绑定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072921281394c1a3a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072921281394c1a3a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999002224.SGD","LU1934455194.USD","LU1989772840.SGD","LU0965509101.SGD","LU0106261372.USD","LU0320765646.SGD","SG9999014542.SGD","BK4534","SG9999001176.USD","LU1061106388.HKD","GSK","LU0985320562.USD","600276","SG9999014559.SGD","SG9999014575.USD","LU2023250504.SGD","IE00BJJMRZ35.SGD","SG9999001176.SGD","LU0203347892.USD","LU1116320737.USD","LU1037948541.HKD","SGXZ57979304.SGD","AZ","LU0122379950.USD","LU1037948897.HKD","LU1066051225.USD","LU1699723380.USD","IE00BFTCPJ56.SGD","LU1934455277.USD","BK4532","IE0002141913.USD","LU0098860793.USD","GSK.UK","LU0289739699.SGD","01177","MRK","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU2106854487.HKD","IE00B2B36J28.USD","LU1093756168.USD","LU1941712348.USD","SG9999013999.USD","LU1571399168.USD","LU1069347547.HKD","LU2361045086.USD","LU0965509010.AUD","01276","LU0861579265.USD","SBHMY","LU0203345920.USD","LU2089984988.USD","BK4007"],"gpt_icon":0},{"id":"2555550037","title":"中国生物制药07月29日获主力加仓3202.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555550037","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555550037?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:15","pubTimestamp":1753776919,"startTime":"0","endTime":"0","summary":"07月29日, 中国生物制药股价涨4.14%，报收7.55元，成交金额19.6亿元，换手率1.41%，振幅5.24%，量比1.29。中国生物制药今日主力资金净流入3202.0万元，上一交易日主力净流入2.8亿元。该股近5个交易日上涨10.00%，主力资金累计净流入3.4亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入13.6亿元，其中净流入天数为17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729165046a6c78078&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729165046a6c78078&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1589","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1191","IE00BZ08YT58.USD","BK1521","01177"],"gpt_icon":0},{"id":"2555828710","title":"全线大张！三大利好刺激，创新药赛道大爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2555828710","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555828710?lang=zh_cn&edition=full","pubTime":"2025-07-29 13:50","pubTimestamp":1753768228,"startTime":"0","endTime":"0","summary":"创新药赛道大爆发。7月29日，A股、港股市场创新药板块再度全线爆发，多只个股大涨超10%。消息面上，创新药赛道大涨主要受业绩超预期、海外大订单与政策三大利好驱动。光大证券指出，考虑到部分创新药公司BD交易持续催化、细分赛道及正处于转型阶段的公司或有积极变化，应当积极关注板块高质量标的、增加板块配置。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291350409724b29a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291350409724b29a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","06127","LU1997245094.SGD","SBHMY","01530","03347","LU2488822045.USD","688221","06821","BK0028","LU0405327148.USD","GSK","BK0196","02359","LU1328615791.USD","159992","02096","603456","LU2328871848.SGD","688321","LU1064130708.USD","01276","BK0060","LU1969619763.USD","BK0183","LU1064131003.USD","LU1997245177.USD","603127","LU1655091616.SGD","LU1997244956.HKD","603367","600276","00853","LU2148510915.USD","BK0012","603229","01093","LU0405327494.USD","603259","BK0239","02186","01177","LU2495084118.USD"],"gpt_icon":0},{"id":"2554242097","title":"东方证券：小核酸药物治疗潜力显现 关注潜在BD机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2554242097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554242097?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:52","pubTimestamp":1753692765,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，小核酸药物能解决小分子和抗体等传统药物不能解决的临床需求，极有可能成为产生大量产品的新技术路径。随着小核酸药物在常见慢病领域治疗潜力的释放，未来有望持续诞生重磅BD。风险提示创新药研发失败风险、市场竞争加剧导致产品大幅降价风险、产品销售和BD不及预期的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","IE00BZ08YS42.EUR","03958","BK1147","600958","BK1564","BK0276","IE00BZ08YT58.USD","BK1589","LU2488822045.USD","BK1583","BK0028","LU2328871848.SGD","BK1521","LU1969619763.USD","BK0183","BK1515","BK0012","IE00BZ08YR35.GBP","01801","01177","BK1191","BK1161"],"gpt_icon":0},{"id":"2554672566","title":"港股异动 | 创新药概念多数走高 行业迎政策红利密集释放期 BD有望加速创新药重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2554672566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554672566?lang=zh_cn&edition=full","pubTime":"2025-07-28 14:52","pubTimestamp":1753685525,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1997244956.HKD","LU1997245094.SGD","LU1064131003.USD","03692","BK0196","LU2148510915.USD","BK1521","LU2328871848.SGD","BK0239","600276","LU1969619763.USD","BK0188","LU2495084118.USD","BK1583","BK1515","LU1655091616.SGD","159992","LU0405327148.USD","LU2488822045.USD","06978","BK0012","BK0183","LU0405327494.USD","BK1593","LU1064130708.USD","02096","BK0028","01801","BK0060","01530","BK1191","BK1161","BK1574","LU1997245177.USD","BK1589","01276","IE00BZ08YT58.USD","01177","LU1328615791.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2554747987","title":"港股异动 | 中生制药(01177)再涨超6% 机构称BD交易有望成为公司的经常性收入和利润来源","url":"https://stock-news.laohu8.com/highlight/detail?id=2554747987","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554747987?lang=zh_cn&edition=full","pubTime":"2025-07-28 11:26","pubTimestamp":1753673211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中生制药再涨超6%，年内累计涨幅已近130%。据悉，中生制药7月15日宣布，以超5亿美元净额收购礼新医药近95.09%股份。中银国际发表研报称，考虑到礼新医药多项资产在全球市场拥有一定潜力，预期中生制药有1至2宗授权交易变得更具可见性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","IE00BZ08YR35.GBP","01477","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1589","BK1521","01177","BK1515"],"gpt_icon":0},{"id":"2554500737","title":"创新药暴涨之后到位了吗？汇丰：下半年还有三大催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2554500737","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554500737?lang=zh_cn&edition=full","pubTime":"2025-07-25 11:37","pubTimestamp":1753414629,"startTime":"0","endTime":"0","summary":"汇丰认为，下半年即将密集公布的学术成果、持续涌现的海外业务发展（BD）交易，以及政策面的支持将支撑医药板块的上涨势头。中国创新药企的价值潜力尚未被市场完全消化，未来仍有进一步上行空间。","market":"us","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3751855","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3751855","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4521","LU0310800965.SGD","LU0128525689.USD","BK1161","03692","01177","BK1574","LU0052756011.USD","LU1267930227.SGD","BK4585","01801","BK4588","02269","LU2236285917.USD","BK4207"],"gpt_icon":1},{"id":"2554327677","title":"港股异动 | 中生制药(01177.HK)再涨超4% 附属礼新医药LM-350获得美国FDA的IND批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2554327677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554327677?lang=zh_cn&edition=full","pubTime":"2025-07-25 09:59","pubTimestamp":1753408758,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","01177","BK1515","BK1521","159938","BK1574","BK1589","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","01477","BK1161","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2552456377","title":"2025年全球医药行业收购活动活跃，又一家跨国药企发起“补强型并购“！","url":"https://stock-news.laohu8.com/highlight/detail?id=2552456377","media":"制药网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552456377?lang=zh_cn&edition=full","pubTime":"2025-07-18 11:08","pubTimestamp":1752808126,"startTime":"0","endTime":"0","summary":"整个交易，预计将于2025年第三季度完成。实际上，天境生物收购Bridge Health的案例也是全球医药行业并购活动愈加活跃的体现。2025年，全球医药行业的大型并购活动频繁，且呈现出创新靶点争夺、技术平台整合与区域市场渗透三大趋势。收购完成后，礼新医药将成为中国生物制药全资子公司。总的来说，2025年医药并购呈现“创新驱动、本土崛起、CNS复兴”三大特点，跨国药企通过收购填补专利悬崖缺口，而中国药企则正通过整合本土Biotech加速国际化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1917777945.USD","LU1116320901.HKD","LU2106854487.HKD","LU0098860793.USD","LU1023059063.AUD","LU1057294990.SGD","BK4534","BK4559","IMAB","LU0070302665.USD","IE00BFTCPJ56.SGD","SG9999014559.SGD","LU2023250843.SGD","LU1989771016.USD","LU1941712348.USD","LU0265550359.USD","LU1061106388.HKD","LU1585245621.USD","LU2361044949.HKD","LU1571399168.USD","IE00BBT3K403.USD","LU1035773651.USD","LU1983299246.USD","LU0289739699.SGD","LU0208291251.USD","01177","LU0965509283.SGD","LU1989772923.USD","LU1941712264.USD","LU1066053197.SGD","LU0965509101.SGD","SBHMY","SG9999013999.USD","LU0320765646.SGD","LU1093756168.USD","LU0238689110.USD","LU1066051498.USD","IE0009355771.USD","IE00B1BXHZ80.USD","LU0122379950.USD","LU0861579265.USD","IE000M9KFDE8.USD","LU0265550946.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1974910355.USD","LU1934455277.USD","LU0965509010.AUD","MRK","LU2361044865.SGD","SG9999014575.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2552458176","title":"“并购之王”初露峥嵘，中国pharma新时代开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2552458176","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552458176?lang=zh_cn&edition=full","pubTime":"2025-07-18 09:31","pubTimestamp":1752802263,"startTime":"0","endTime":"0","summary":"/ 01 / 中国pharma开启并购新时代中国生物制药此次并购的一个焦点是：国内制药产业并购时代的开启。类似中国生物制药这类大pharma，“临床开发实力、制造能力和商业影响力”均属于业界公认的顶流。眼下，中国生物制药的强力出击，无疑是中国pharma开始角逐并购市场的积极信号。在中国生物制药带动下，更多中国pharma必然会加入并购队伍。属于中国phrama的并购大时代，已经拉开大幕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071809312697aa7a3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071809312697aa7a3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","01177","BK1521","BK1161","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1191","09939","IE00BZ08YR35.GBP","BK1589"],"gpt_icon":0},{"id":"2552489500","title":"“并购之王”初露峥嵘，中国pharma新时代开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2552489500","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552489500?lang=zh_cn&edition=full","pubTime":"2025-07-17 18:54","pubTimestamp":1752749676,"startTime":"0","endTime":"0","summary":"中国pharma开启并购新时代中国生物制药此次并购的一个焦点是：国内制药产业并购时代的开启。类似中国生物制药这类大pharma，“临床开发实力、制造能力和商业影响力”均属于业界公认的顶流。眼下，中国生物制药的强力出击，无疑是中国pharma开始角逐并购市场的积极信号。在中国生物制药带动下，更多中国pharma必然会加入并购队伍。属于中国phrama的并购大时代，已经拉开大幕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717195155a6afc408&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717195155a6afc408&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4516","BK4007","IE00B1BXHZ80.USD","LU0985320562.USD","LU0965509010.AUD","LU1093756168.USD","LU2461242641.AUD","IE00BBT3K403.USD","BK4534","IE00BLSP4239.USD","IE00B4R5TH58.HKD","LU0238689110.USD","LU1066051498.USD","LU2106854487.HKD","IE00BJT1NW94.SGD","LU0965509283.SGD","LU2468319806.SGD","LU0058720904.USD","LU2023250504.SGD","LU1934455277.USD","SG9999014575.USD","MRK","IE0002141913.USD","LU1934455194.USD","BK4533","LU0289739699.SGD","SG9999001440.SGD","LU1116320737.USD","LU1037948897.HKD","LU0106261372.USD","LU0965509101.SGD","SG9999013999.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU0265550359.USD","LU1093756325.SGD","LU1057294990.SGD","L","SG9999001176.USD","LU1941712264.USD","LU1162221912.USD","LU1061106388.HKD","LU1037948541.HKD","IE00BN8TJ469.HKD","01177","LU1066053197.SGD","LU0006306889.USD","LU1571399168.USD","LU0965508806.USD","LU1989772840.SGD"],"gpt_icon":0},{"id":"2552248620","title":"中生收购礼新说明会现场，秦莹否认默沙东退货传言","url":"https://stock-news.laohu8.com/highlight/detail?id=2552248620","media":"MedTrend医趋势","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552248620?lang=zh_cn&edition=full","pubTime":"2025-07-17 18:11","pubTimestamp":1752747074,"startTime":"0","endTime":"0","summary":"7月17日上午10点30-11点40，中国生物制药就收购礼新医药在香港召开说明会，中国生物制药董事会主席谢其润女士与礼新医药创始人、董事长兼首席执行官为秦莹博士出席现场。以及传出的默沙东退货话题。现场，两位负责人也分别作出解释。随后，中国生物制药宣布与礼新医药签署股权投资及战略合作协议。而中国生物制药也一直关注礼新医药，目前礼新医药已建成全球领先的抗体发现和ADC技术平台，是全市场唯一同时被MNC认可的双抗+ADC平台。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","LU1069347547.HKD","LU1571399168.USD","IE0002141913.USD","LU1093756325.SGD","LU2361044865.SGD","IE00BLSP4239.USD","LU0965508806.USD","LU1934455277.USD","LU2023250843.SGD","LU0238689110.USD","MRK","SG9999014559.SGD","BK4550","LU0006306889.USD","LU1699723380.USD","LU0106261372.USD","LU0965509010.AUD","SG9999001440.SGD","SG9999002232.USD","SG9999002224.SGD","LU1929549753.HKD","LU1037948897.HKD","LU1037948541.HKD","SG9999014575.USD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU2461242641.AUD","IE00B1BXHZ80.USD","BK4516","BK4559","BK4588","LU0070302665.USD","LU0058720904.USD","LU2106854487.HKD","LU0234572021.USD","IE00BN8TJ469.HKD","IE00BJJMRZ35.SGD","LU1989771016.USD","LU2361045086.USD","LU1116320737.USD","01177","LU2324357040.USD","LU0985320562.USD","LU2112291526.USD","LU2468319806.SGD","LU1035773651.USD","SBHMY","LU0211331839.USD","LU1066051811.HKD","LU1162221912.USD"],"gpt_icon":0},{"id":"1141350001","title":"异动解读 | 中国生物制药斥资68亿收购礼新医药，股价盘中大涨7.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141350001","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141350001?lang=zh_cn&edition=full","pubTime":"2025-07-17 15:53","pubTimestamp":1752738818,"startTime":"0","endTime":"0","summary":"周四中午，中国生物制药股价盘中大涨7.3%，引发市场关注。近日，中国生物制药公告称，公司拟以不超过9.51亿美元收购礼新医药95.09%股权。加上此前持有的4.91%股权，交易完成后礼新医药将成为中国生物制药全资子公司。分析人士认为，这笔收购展现了中国生物制药在创新药领域的战略布局，有望进一步增强公司的核心竞争力和国际影响力。投资者普遍看好此次收购将为中国生物制药带来长期增长动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2552910874","title":"中国生物制药升目标价至7.6港元，维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2552910874","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552910874?lang=zh_cn&edition=full","pubTime":"2025-07-17 13:13","pubTimestamp":1752729233,"startTime":"0","endTime":"0","summary":"中金发布研报称，维持中国生物制药盈利预测不变和“跑赢行业”评级，当前股价交易于29.0/26.1倍2025/2026年P/E，考虑板块估值中枢上行，上调目标价26.7%到7.6港元，对应34.6/31.1倍2025/2026年P/E，隐含19.3%上行空间。7月15日晚，公司公告将以总对价9.5092亿美元收购礼新医药95.09%股权。中国生物制药已持有4.91%股权，收购完成后，礼新医药将成为中国生物制药全资子公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717133042a45038ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717133042a45038ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01548","SBHMY","01177"],"gpt_icon":0},{"id":"1136202340","title":"异动解读 | 中国生物制药盘中大涨5.12%，68亿收购礼新医药加码创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1136202340","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136202340?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:38","pubTimestamp":1752716309,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨5.12%，引发市场关注。首先，中国生物制药于7月15日晚间宣布，拟以不超过9.51亿美元收购礼新医药95.09%股权。加上此前持有的4.91%股权，交易完成后礼新医药将成为中国生物制药全资子公司。此次收购将显著扩充中国生物制药的创新药管线，尤其是在肿瘤领域的研发实力，有望增强公司的核心竞争力和国际影响力。这些积极因素共同推动了中国生物制药股价的强劲表现，反映出市场对公司战略布局和发展前景的看好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2552172185","title":"焦点板块及个股 | 医药行业；科技行业；高盛；软银集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2552172185","media":"中信证券财富管...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552172185?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:15","pubTimestamp":1752714945,"startTime":"0","endTime":"0","summary":"头部药企业绩即将进入加速阶段，建议投资者下半年“逢低布局、持有为主”。科技行业 - 海外 AI 应用已经从 token 消耗和收入等维度逐步验证实际商业价值今年以来海外 AI 应用呈现加速态势。业绩公布后，公司股价周三靠稳涨0.90%。虽然很难想象大规模回购会在未来几年成为主要因素，但对于OpenAI的好消息以及IPO的预期兴奋将被视为积极因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092907a44fc4dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092907a44fc4dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","LU1152091168.USD","LU0315179316.USD","IE0008368742.USD","BK1521","LU1226288253.USD","01177","LU1226287529.USD","LU1152091754.HKD","LU1226288170.HKD","IE00B031HY20.USD","GS","IE0008369823.USD","09988","IE00BZ08YR35.GBP","LU1226287792.SGD","LU0072913022.USD","LU1008478684.HKD","LU1993786604.SGD","89988","LU1951186391.HKD","LU0880133367.SGD","LU1807302812.USD","BK1515","LU1226287875.USD","SG9999004220.SGD","IE00BZ08YS42.EUR","LU0501845795.SGD","01093","03692","LU1960683339.HKD","LU0140636845.USD","IE00B543WZ88.USD","LU0326950275.SGD","BK1191","IE00BZ08YT58.USD","LU0067412154.USD"],"gpt_icon":0},{"id":"2552206701","title":"中国生物制药拟68亿元收购创新药企礼新医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2552206701","media":"证券日报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552206701?lang=zh_cn&edition=full","pubTime":"2025-07-17 00:38","pubTimestamp":1752683909,"startTime":"0","endTime":"0","summary":"【中国生物制药拟68亿元收购创新药企礼新医药】7月15日晚间，港股上市公司中国生物制药发布公告称，拟以不超过9.51亿美元（约合人民币68.22亿元）收购上海礼新医药科技股份有限公司（以下简称“礼新医药”）95.09%股权。加上此前参与礼新医药C轮融资时取得的4.91%股权，交易完成后，礼新医药将成为中国生物制药全资子公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507173459151645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","09939","IE00BZ08YS42.EUR","06978","IE00BZ08YT58.USD","BK1515","IE00BZ08YR35.GBP","01177","BK1191","BK1589","BK1521"],"gpt_icon":0},{"id":"2552106892","title":"港股医药：板块表现强势 建议积极增加配置","url":"https://stock-news.laohu8.com/highlight/detail?id=2552106892","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552106892?lang=zh_cn&edition=full","pubTime":"2025-07-17 00:00","pubTimestamp":1752681600,"startTime":"0","endTime":"0","summary":"年初至今恒生医疗保健指数表现靓丽。关注盈利改善和BD 交易的实质性进展机会，建议积极增加板块配置。港股医药板块估值收缩已持续数年，部分优质企业PE 估值在反弹后仍具吸引力。考虑到部分创新药公司BD 交易持续催化、细分赛道及正处于转型阶段的公司或有积极变化，我们认为应当积极关注板块高质量标的、增加板块配置。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717141220a4504a5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717141220a4504a5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1585","BK1589","01093","00867","00853","01530","BK1583","01177","01066"],"gpt_icon":0},{"id":"2551475781","title":"执行董事谢炘增持中国生物制药(01177)100万股 每股作价6.47港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551475781","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551475781?lang=zh_cn&edition=full","pubTime":"2025-07-16 18:51","pubTimestamp":1752663077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月16日，执行董事谢炘增持中国生物制药(01177)100万股，每股作价6.47港元，总金额为647万港元。增持后最新持股数目约为3.59亿股，持股比例为1.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"执行董事谢炘增持中国生物制药(01177)100万股 每股作价6.47港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1521","BK1515","01177","IE00BZ08YS42.EUR","BK1589","BK1191"],"gpt_icon":0},{"id":"2551414421","title":"累计对外授权近300亿后，上海“创新药黑马”拟易主，中生制药超35亿收购礼新医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551414421","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551414421?lang=zh_cn&edition=full","pubTime":"2025-07-16 17:44","pubTimestamp":1752659092,"startTime":"0","endTime":"0","summary":"7月15日晚间，中生制药对外宣布，其将以约5亿美元的净代价收购礼新医药95.09%股权。加上此前持有的4.91%股权，此次交易完成后，礼新医药将成为中生制药间接全资附属公司。截至目前，礼新医药累计对外授权近40亿美元，折合人民币近300亿元。这并非中生制药与礼新医药的首次牵手。近年来，传统药企正在加速向创新药方向转型，中生制药也不例外。交易完成后，浩欧博将成为中生制药旗下第一家A股上市公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071617451997a84632&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071617451997a84632&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159938","159992","01177","688656"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0942},{"period":"1month","weight":0.4245},{"period":"3month","weight":0.9449},{"period":"6month","weight":1.6964},{"period":"1year","weight":1.7615},{"period":"ytd","weight":1.3765}],"compareEarnings":[{"period":"1week","weight":0.0157},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.1539},{"period":"6month","weight":0.262},{"period":"1year","weight":0.4807},{"period":"ytd","weight":0.2724}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一间主要从事药品业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部主要从事长期及短期投资。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.409091,"avgChangeRate":0.005049},{"month":2,"riseRate":0.681818,"avgChangeRate":0.062788},{"month":3,"riseRate":0.590909,"avgChangeRate":0.049122},{"month":4,"riseRate":0.5,"avgChangeRate":0.025813},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043238},{"month":6,"riseRate":0.363636,"avgChangeRate":0.009797},{"month":7,"riseRate":0.636364,"avgChangeRate":0.048528},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.014693},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.015856},{"month":10,"riseRate":0.571429,"avgChangeRate":0.032604},{"month":11,"riseRate":0.52381,"avgChangeRate":0.069192},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.006395}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}